SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-056948
Filing Date
2024-05-09
Accepted
2024-05-09 16:10:17
Documents
13
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lctx-20240509.htm   iXBRL 8-K 39651
2 EX-99.1 lctx-ex99_1.htm EX-99.1 318931
3 GRAPHIC img176613450_0.jpg GRAPHIC 40991
  Complete submission text file 0000950170-24-056948.txt   544440

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lctx-20240509.xsd EX-101.SCH 23882
16 EXTRACTED XBRL INSTANCE DOCUMENT lctx-20240509_htm.xml XML 4516
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

IRS No.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 24930650
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)